Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Q32 Bio Inc.FIXX · Entity 5594 | Chief Medical Officer | January 01, 2022 | January 12, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Q32 Bio Inc.
Report date January 01, 2022 · Filed January 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,629 |
Ending reported balance
After 2022-01-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-01-01 · Exercise / conversion · Acquired 4,290 · Balance 4,290 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Row 2 · 2022-01-05 · Sale · Disposed 1,661 · Balance 2,629 F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs. F3: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $3.78 to $3.79. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,710 |
Reported balance
After 2022-01-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-01-01 · Exercise / conversion · Disposed 4,290 · Balance 8,710 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4: The RSUs have vested and settled or will vest and settle, as applicable, as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs.
F3: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $3.78 to $3.79. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.
F4: The RSUs have vested and settled or will vest and settle, as applicable, as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2022 Filed Jan 12, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 1,661 | $3.78 | $6,278.75 |
DisclosureSEC source: 0000899243-22-001745 · doc4.xml · nonDerivative · entry 2 Cohn Gabriel · CIK 0001794702 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,629 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $3.78 to $3.79. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. Read SEC document |
| January 01, 2022 Filed Jan 12, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 4,290 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001745 · doc4.xml · derivative · entry 3 Cohn Gabriel · CIK 0001794702 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,710 Underlying: Common Stock · 4,290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The RSUs have vested and settled or will vest and settle, as applicable, as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. F4 · derivative.expiration_date: The RSUs have vested and settled or will vest and settle, as applicable, as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. Read SEC document |
| January 01, 2022 Filed Jan 12, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 4,290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001745 · doc4.xml · nonDerivative · entry 1 Cohn Gabriel · CIK 0001794702 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:22 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantRestricted Stock Units · Derivative | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-005456 · doc4.xml · derivative · entry 2 Cohn Gabriel · CIK 0001794702 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. F3 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:22 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 78,000 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0000899243-21-005456 · doc4.xml · derivative · entry 1 Cohn Gabriel · CIK 0001794702 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2031-02-05 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following January 1, 2021. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:07 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $19.92 | $0.00 |
DisclosureSEC source: 0000899243-19-029157 · doc4.xml · derivative · entry 1 Cohn Gabriel · CIK 0001794702 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-12-11 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following January 1, 2020. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:09 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $17.14 | $0.00 |
DisclosureSEC source: 0000899243-19-028397 · doc4.xml · derivative · entry 1 Cohn Gabriel · CIK 0001794702 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2029-12-02 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was December 2, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.